北京英诺特生物技术股份有限公司关于公司近期获得资质情况的自愿披露公告

Group 1 - The company has recently obtained two new product qualifications, enhancing its capabilities in detecting low-abundance biomarkers, particularly for neurodegenerative diseases like Alzheimer's [1] - The approved products utilize single-molecule array detection technology, significantly improving sensitivity compared to traditional immunoassays, with a detection limit at the fg level (1 fg = 10^-12 mg) [1] - The ability to simultaneously detect multiple biomarkers represents a technological leap from traditional immunoassays to single-molecule precision detection, providing critical support for ultra-early diagnosis of diseases [1] Group 2 - The acquisition of these qualifications broadens the company's product range and enhances its market expansion capabilities and core competitiveness [2]